Junfeng Zhang | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Assoc. Prof. Dr. Junfeng Zhang | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Junfeng Zhang, Anhui University of Science and Technology, China

Dr. Junfeng Zhang is an Associate Professor and Deputy Director of the Center for Medical Frontiers at the School of Medicine, Anhui University of Science and Technology. With a Ph.D. in biomedical sciences, he has emerged as a leading figure in nanomedicine and cancer theranostics. His work integrates nanotechnology, molecular imaging, and drug delivery systems, particularly focusing on intelligent nanoformulations for tumor targeting and integrated diagnostics and therapy. Dr. Zhang is an active member of multiple national medical committees and has contributed significantly to interdisciplinary research. His publications in prestigious journals like Advanced Materials, Small Methods, and Advanced Science reflect both scientific depth and translational potential. As a council and committee member of several medical and health associations, he actively promotes collaboration across academic and healthcare institutions. His dedication to innovation and public health positions him as a rising star in biomedical engineering and personalized cancer therapy.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. High-Impact Research Contributions

    • Dr. Zhang has published in top-tier international journals such as Advanced Materials (IF: 32.086), Advanced Science (IF: 15.1), and Small Methods (IF: 15.367).

    • His work demonstrates interdisciplinary excellence—combining nanotechnology, oncology, and imaging science to address complex medical challenges.

  2. Innovative Scientific Focus

    • Focused on intelligent theranostic nanoformulations, his research targets both diagnostic imaging and cancer therapy in a single platform.

    • He has developed laser-free imaging systems, nucleus-targeted drug delivery platforms, and responsive nanosystems, which are highly relevant to personalized and precision medicine.

  3. Leadership & Recognition

    • Serves as the Deputy Director of the Center for Medical Frontiers, showing strategic leadership.

    • Holds multiple national-level committee memberships, indicating peer recognition and influence in the field of nuclear medicine, digital health, and environmental mutagen studies.

  4. Collaborative & Global Research Impact

    • Frequently collaborates with international researchers like Prof. Rui L. Reis.

    • Demonstrates versatility in both experimental and translational research, addressing real-world medical and toxicological issues.

  5. Consistent Productivity

    • Maintains a consistent and strong publication record as first/corresponding author over the past five years, with multi-disciplinary themes.

⚠️ Areas for Improvement:

  1. Commercialization & Patent Activity

    • While his work is scientifically advanced, there is limited visible emphasis on patent filings, technology transfer, or startup ventures. Increasing focus here would enhance his profile for innovation-based awards.

  2. International Outreach

    • Although involved in collaborations, more visibility in international scientific conferences, editorial boards, or global awards could further strengthen his candidacy on the world stage.

  3. Public Health Engagement

    • As his work is deeply relevant to cancer management, more visible contributions to community awareness, patient education, or policy advisory roles could broaden the societal impact of his research.

🎓 Education:

Dr. Junfeng Zhang earned his doctoral degree (Ph.D.) in biomedical sciences, with a specialization in nanomedicine and molecular diagnostics. While the specific university name is not listed, the rigorous research output suggests training from a high-caliber institution. His education integrated core principles of pharmacology, biomedical engineering, and cancer biology, allowing him to build a strong foundation in interdisciplinary medical research. During his academic career, he focused on translational research that merges engineering, imaging technologies, and clinical applications. Through his doctoral training, Dr. Zhang acquired advanced techniques in nanoparticle synthesis, fluorescence imaging, and drug delivery. His education paved the way for impactful research in photoacoustic imaging and intelligent targeted therapies. Dr. Zhang’s academic background equipped him to lead cutting-edge research projects that align with global challenges in oncology. He continues to leverage his academic foundation to mentor graduate students and drive innovation in healthcare technology development.

🧪 Experience:

Dr. Zhang currently serves as Associate Professor and Deputy Director of the Center for Medical Frontiers at the School of Medicine, Anhui University of Science and Technology. He holds prominent roles including Council Member of the Anhui Provincial Society of Environmental Mutagens and committee memberships in nuclear medicine and digital health bodies. With over five years of experience in biomedical research and teaching, he has led numerous research projects at the interface of nanomedicine, cancer biology, and imaging diagnostics. His international collaborations and editorial contributions signify global recognition. As a mentor, he guides students and young researchers in clinical translation of nano-based therapies. His leadership at the Center for Medical Frontiers emphasizes high-impact innovation, collaborative research culture, and practical solutions to oncological diseases. His diverse experience in academic, clinical, and committee roles demonstrates his comprehensive influence in shaping future medical technologies and public health strategies.

🔬 Research Focus:

Dr. Zhang’s research focuses on the development of intelligent theranostic nanoformulations aimed at achieving both diagnosis and treatment of tumors in a single platform. His work emphasizes dual-mode imaging systems (photoacoustic/fluorescence), targeted drug delivery, and biocompatible nanocarriers capable of bypassing biological barriers. One of his key innovations involves creating gold- and carbon-based nanomaterials for laser-free imaging and mitochondrial apoptosis induction. He is particularly interested in nucleus-targeted therapies, precision drug delivery, and responsive nanosystems that adjust to tumor microenvironments. He also studies the toxicological aspects of nanomedicines under various physiological conditions, including magnetic field exposure and metabolic pathway disruptions. His research bridges disciplines like pharmacology, materials science, and medical imaging, contributing to the personalized medicine movement. With a strong publication record in high-impact journals, his research focus reflects a commitment to translating laboratory innovations into clinical applications to improve cancer diagnosis, treatment precision, and therapeutic outcomes.

📚 Publications Top Notes:

  1. 🧬 A Multifunctional Photoacoustic/Fluorescence Dual-Mode-Imaging Gold-Based Theranostic Nanoformulation without External Laser Limitations – Advanced Materials, 2022

  2. 💊 An Efficient Carbon-Based Drug Delivery System for Cancer Therapy through the Nucleus Targeting and Mitochondria Mediated Apoptotic Pathway – Small Methods, 2021

  3. 🧠 Humanistic Health Management and Cancer: Associations of Psychology, Nutrition, and Exercise with Cancer Progression and Pathogenesis – Advanced Science, 2024

  4. 🌿 Preparation, Characterization, and Evaluation of the Antitumor Effect of Kaempferol Nanosuspensions – Drug Delivery and Translational Research, 2023

  5. 🐟 High Concentrations of Fluorescent Nanoprobes Delayed Oryzias Melastigma Embryo Hatching by Modulating Respiratory and Metabolic Pathways – VIEW, 2025

  6. 🧲 The Biokinetics and Toxicology of Fe₃O₄ Nanoparticles Influenced by Magnetic Field and Protein – Nano, 2022

🧾 Conclusion:

Dr. Junfeng Zhang is a highly suitable and deserving candidate for the Best Researcher Award. His cutting-edge work in nanomedicine, combined with consistent high-impact publications, academic leadership, and contributions to national scientific bodies, clearly mark him as a rising and influential scientist in the medical research community. With slight enhancements in technology translation and international public engagement, he holds potential to become a global leader in biomedical innovation.

Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Prof. Dr. Raphael Borie, APHP, France

Dr. Raphaël Borie, born on August 15, 1977, in Paris, France, is a leading expert in pulmonology and genetic respiratory diseases. Currently a University Professor Hospital Practitioner at Bichat Hospital (Paris Cité University), he has consistently contributed to the advancement of respiratory medicine, particularly in the field of interstitial lung diseases (ILDs). His clinical insight, combined with a strong research portfolio, has positioned him as a prominent figure within the OrphaLung network. A dedicated family man with two children, Dr. Borie is widely respected for his integrity, leadership, and commitment to collaborative medicine. His career reflects a unique blend of academic excellence and impactful translational research, bridging the gap between genomics and clinical care in ILD. He is a registered member of the French Medical Council (Ordre des Médecins No. 75/71138), and his research has influenced European clinical guidelines and improved the understanding of rare genetic pulmonary conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Robust Academic Background:
    Dr. Borie holds a PhD in Genetics, Master’s in Physiology, and HDR (habilitation to supervise doctoral research), which underlines his scientific credibility and ability to lead independent research.

  2. Clinical-Research Integration:
    As a University Professor and Hospital Practitioner, he merges frontline patient care with cutting-edge genetic and respiratory disease research.

  3. High Publication Impact:
    With 283 PubMed-indexed articles and an H-index of 60, Dr. Borie’s work demonstrates strong citation influence, indicating widespread recognition and utility in the scientific community.

  4. International Leadership:
    Active in multinational collaborations (e.g., OrphaLung, ERS), he has co-authored major position statements and clinical trials, influencing European respiratory care guidelines.

  5. Innovation in Rare Diseases:
    A recognized expert in familial interstitial lung disease and telomere disorders, his work has led to earlier diagnosis and targeted therapies—critical in fields where few experts exist.

  6. Recognition and Funding:
    He has secured prestigious mobility grants (ERS, Respirology Teachers College)—a marker of trust in his scientific mission and innovation.

🔍 Areas for Improvement:

  • Wider Public Health Translation: While Dr. Borie’s genomic research is exceptional, expanding into real-world health policy implementation could enhance systemic impact.

  • Patient Engagement & Advocacy: Developing patient-oriented tools or registries (e.g., digital apps or platforms for familial lung diseases) may broaden his outreach beyond academia and clinics.

  • Broader Visibility: Although highly cited in professional circles, participation in international keynote talks, editorial leadership, or mainstream health media could elevate his public and professional visibility.

🎓 Education:

Dr. Borie has pursued an extensive and rigorous academic path focused on respiratory and genetic medicine. He obtained his medical degree with specialization in Allergology and Immunopathology in 2006. A year earlier, in 2005, he earned a Master’s degree in Biology and Physiology of Circulation and Respiration. Demonstrating deep interest in genetics, he completed a PhD in Genetics in 2017, contributing significantly to our understanding of genetic underpinnings in pulmonary fibrosis. In 2019, Dr. Borie achieved the prestigious Habilitation à Diriger des Recherches (HDR) from the University of Paris 7, enabling him to supervise doctoral research. His academic background illustrates a powerful integration of clinical expertise and molecular research—providing him with the tools to lead innovative research projects at the intersection of genomics and pulmonology.

🩺 Experience:

Dr. Raphaël Borie has over 15 years of experience in respiratory medicine. From July 2011 to August 2020, he served as a Hospital Practitioner in the Pneumology Department at Bichat Hospital under Professors Aubier and Crestani. Since September 2020, he has been a University Professor Hospital Practitioner in the same department, affiliated with Paris Cité University. He has contributed to patient care, education of medical students and residents, and cutting-edge research. As part of the OrphaLung network, he plays a critical role in advancing diagnostic tools and treatment approaches for rare lung diseases. He is recognized for his collaborative leadership and interdisciplinary contributions across genetics, immunology, and pulmonology. His international collaborations and authorship of over 280 PubMed-indexed publications demonstrate his ongoing commitment to improving patient outcomes through translational research.

🏆 Awards and Honors:

Dr. Borie’s research excellence has been recognized through several prestigious awards and scholarships. In 2017, he received the European Respiratory Society (ERS) Mobility Grant for his work on Identification of Preclinical Markers of Pulmonary Fibrosis, supporting international collaboration and advanced training. The same year, he was also honored with the Respirology Teachers College Mobility Grant, reinforcing his pioneering research on early detection of fibrotic lung disease. His selection for these awards highlights both scientific innovation and dedication to knowledge exchange. His leadership in multi-center studies and involvement in ERS guideline statements further reflect his status as a thought leader in interstitial lung disease. These honors are a testament to his influence in shaping the future of pulmonary genetics and translational respiratory medicine.

🔬 Research Focus:

Dr. Raphaël Borie’s research centers on familial and genetic interstitial lung diseases, particularly the molecular mechanisms behind pulmonary fibrosis, telomere biology, surfactant-related gene variants, and early detection strategies. He works extensively on identifying genetic risk variants (e.g., MUC5B, DSP) and their implications in idiopathic pulmonary fibrosis. Through his participation in the OrphaLung network, he supports genomic screening for hereditary lung disorders and contributes to developing European guidelines. His work bridges genomic medicine and clinical pulmonology, aiming for earlier diagnosis and personalized treatment approaches. He has led and co-authored critical studies on RTEL1 mutations, telomerase complex defects, and familial ILD phenotypes, helping clinicians globally understand the heterogeneity and systemic implications of genetic lung disorders. His collaborative international research ensures his findings are applied in practice to optimize long-term patient care.

📚Publications Top Notes:

  • 🧬 High risk of lung cancer in surfactant-related gene variant carriers – Eur Respir J, 2024

  • 📄 European Respiratory Society Statement on Familial Pulmonary Fibrosis – Eur Respir J, 2022

  • 🧪 Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants – Am J Respir Crit Care Med, 2022

  • 🧬 RTEL1 mutations and their phenotypic variability – Eur Respir J, 2019

  • 💊 Safety and efficacy of pirfenidone in telomerase mutation carriers – Eur Respir J, 2018

  • 🌐 Diagnosis and follow-up of familial ILD: International survey – BMC Pulmonary Med, 2025

  • 🧬 New 2023 ACR/EULAR APS criteria performance in young patients – Letter, 2025

  • 🫁 A non-resolving cough: a case of familial pulmonary fibrosis – Breathe, 2025

  • 🧬 PFMG2025: Genomic medicine in French healthcare system – Review, 2025

  • 💊 Efficacy of CFTR modulators in ABCA3-deficiency ILD – Open Access, 2025

  • 🧠 Neurological manifestations in VEXAS syndrome – Journal of Neurology, 2025

  • 💉 Real-life use of PEXIVAS reduced-dose regimen in vasculitis – Ann Rheum Dis, 2025

  • 🧫 Recurrent respiratory papillomatosis with lung involvement – Eur Respir J, 2025

  • 🔍 RA-ILD: genetics to clinical overview – Review, 2025

  • 👶 Childhood ILD survivors in adulthood: European study – Eur Respir J, 2025

🧾 Conclusion:

Dr. Raphaël Borie exemplifies the ideal candidate for the Best Researcher Award. His excellence spans across clinical expertise, academic distinction, and international research leadership, especially in genetic and familial interstitial lung diseases—a field with enormous unmet need. His consistent scholarly output, impactful collaborations, and patient-focused studies highlight a unique blend of depth and innovation. While further expansion into public health frameworks and patient engagement tools would be valuable, his profile already reflects a world-class researcher with transformative contributions to pulmonary medicine.

SANKALP MISRA | Microbiology | Best Researcher Award

Posted on by Cell Biologist

Assist. Prof. Dr. SANKALP MISRA | Microbiology | Best Researcher Award

Assist. Prof. Dr. SANKALP MISRA , Shri Ramswaroop Memorial University , India

Dr. Sankalp Misra is a dedicated microbiologist with a Ph.D. in Microbial Technology, currently working as a Research Associate at CSIR-National Botanical Research Institute (NBRI), Lucknow. Born on November 6, 1988, in India, he has cultivated a robust academic and research career focused on plant-microbe interactions and sustainable agriculture. Fluent in both English and Hindi, Dr. Misra has consistently demonstrated a commitment to addressing real-world agricultural challenges through microbiological innovations. His research explores the symbiotic relationships between soil microbes and plants, particularly under stress conditions such as salinity and drought. With a host of fellowships, awards, and scientific publications to his name, Dr. Misra is not only a prolific researcher but also a valued contributor to India’s agricultural biotechnology community. He is a life member of the Association of Microbiologists of India and continues to contribute actively to scientific dialogue and applied research in microbial ecology.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Experience
    Over 10 years of continuous research in microbial biotechnology, especially plant-microbe interactions, bioremediation, and stress physiology, primarily under the CSIR-NBRI—a top-tier research institution in India.

  2. Focused Scientific Contributions
    His Ph.D. work on salt-tolerant plant growth-promoting rhizobacteria (PGPR) addresses crucial agricultural challenges, with implications in sustainable farming and climate-resilient agriculture.

  3. Prolific Publication Record
    Co-authored over 15 research papers and book chapters in high-impact journals and internationally reputed publishers (Springer, Wiley, Academic Press).

  4. Nationally Recognized Fellowships & Awards

    • ICMR Research Associate & Senior Research Fellowship

    • Gold Medalist in B.Sc.

    • Multiple Best Poster Awards in national and international conferences

    • Consistent CSIR-UGC NET success (31st and 47th ranks)

  5. Professional Engagement
    Holds a Life Membership in The Association of Microbiologists of India, reflecting his active involvement in the scientific community.

  6. Interdisciplinary Expertise
    Skilled in proteomics, metagenomics, microbial ecology, and plant stress biology, showcasing an ability to tackle complex problems from multiple biological angles.

⚙️ Areas for Improvement:

  1. International Exposure
    While the research is nationally strong, global collaborations or international fellowships could further elevate the impact and visibility of his work.

  2. Grant Leadership & Independent Projects
    Leading funded projects as a Principal Investigator (PI) would demonstrate further maturity in research leadership and scientific management.

  3. Patent/Technology Transfer
    Translating research into patents, bio-formulations, or industry partnerships could bridge the lab-to-land gap, enhancing the practical application of his findings.

🎓 Education:

Dr. Sankalp Misra completed his Ph.D. in Microbial Technology from CSIR-NBRI, focusing on the “Characterization of salt tolerant plant growth promoting rhizobacteria from different agro-climatic zones of Uttar Pradesh.” Guided by Dr. Puneet Singh Chauhan, his doctoral work laid a foundation in microbial stress biology. He qualified the prestigious CSIR-UGC NET in both 2013 (47th rank) and 2014 (31st rank), showcasing strong academic competence. He also cleared the CET-Ph.D in 2012. His undergraduate studies were marked by excellence, earning a Gold Medal in B.Sc., emphasizing his early commitment to academic rigor. These achievements underline his solid foundation in microbiology, plant biology, and biotechnological research. Throughout his educational journey, Dr. Misra has consistently demonstrated a deep curiosity for microbial applications in agriculture and an aptitude for integrating advanced scientific methods to address pressing challenges in crop sustainability and soil health.

💼 Experience:

Dr. Sankalp Misra has over a decade of research experience in plant-microbe interactions. He is currently an ICMR-Research Associate at CSIR-NBRI since October 2019. Prior roles include ICMR-Senior Research Fellow and several project fellowships at CSIR-NBRI from 2013 to 2019. These positions allowed him to work on key projects involving soil microbiomes, salt and drought stress in plants, and bioremediation. His extensive hands-on experience ranges from lab-based experiments to field applications, focusing on sustainable and ecological approaches in agriculture. He has significantly contributed to the development of microbial formulations and transgenic studies aimed at improving crop resilience. His continuous association with CSIR-NBRI reflects a stable and productive research career. Each role has helped him refine his techniques in molecular biology, microbiome analysis, and biotechnological innovation, making him a competent and valuable researcher in environmental microbiology and sustainable agricultural practices.

🏅 Awards and Honors:

Dr. Misra has received multiple accolades recognizing his scientific excellence. He was awarded the prestigious ICMR Research Associateship (Oct 2019) and Senior Research Fellowship (July 2019), reflecting national-level recognition. His scientific presentations have earned him Best Poster Awards in major conferences, including the 3rd National Seminar on Life Sciences (NSCTLS-2021) and the 6th International Conference on Plants and Environmental Pollution (ICPEP-6, 2018). Academically, he secured top ranks in CSIR-UGC NET (31st in 2014 and 47th in 2013) and earned a Gold Medal in B.Sc., demonstrating exceptional merit throughout his academic and research career. His commitment is further underscored by his life membership in The Association of Microbiologists of India (AMI). These achievements highlight his consistent dedication, peer recognition, and leadership potential in the fields of microbiology and agricultural biotechnology.

🔍 Research Focus:

Dr. Sankalp Misra’s research centers on plant-microbe interactions, especially under environmental stress like salinity and drought. He explores rhizobacteria that promote plant growth and mitigate stress through mechanisms such as ACC deaminase production, metabolomic reprogramming, and soil microbial community enhancement. His interests extend to soil metagenomics, microbial proteomics, and bioremediation, all aimed at achieving sustainable agriculture. A key aspect of his work involves isolating and characterizing stress-tolerant microbes from diverse agro-climatic zones, using them to enhance crop resilience and productivity. His work contributes to global efforts in climate-resilient farming, making him a notable figure in applied agricultural microbiology. He has co-authored numerous high-impact publications and book chapters that explore these themes, confirming his deep engagement in cutting-edge microbial biotechnology.

📚 Publications Top Notes:

  1. 🌱 Enhancement of Drought Tolerance in Transgenic Arabidopsis thaliana Plants Overexpressing Chickpea Ca14-3-3 Gene

  2. 🦠 Novel trends in endophytic applications for plant disease management

  3. 🌍 Rhizobacteria‐Mediated Bioremediation: Insights and Future Perspectives

  4. 🌾 Endospheric Microbiome-Assisted Alteration in the Metabolomic Profiling of Host towards Abiotic Stress Mitigation

  5. 🧬 Revealing the complexity of protein abundance in chickpea root under drought-stress using comparative proteomics

  6. 🔬 Characterization of alkalotolerant Alcaligenes and Bacillus strains for mitigating alkaline stress in Zea mays

  7. 🌿 Drought tolerant Ochrobactrum sp. inoculation helps maintain homeostasis in Zea mays under water stress

  8. ⚗️ ACC deaminase-producing Bacillus spp. mitigate salt stress and enhance Zea mays growth

  9. 🧪 Exploration of Soil Resistome Through a Metagenomic Approach

  10. 🍃 Essential Oils: Potential Application in Disease Management

📝 Conclusion:

Dr. Sankalp Misra is an excellent and deserving candidate for the Best Researcher Award. His consistent contributions to microbial biotechnology, evidenced by a strong portfolio of peer-reviewed publications, government fellowships, and research impact, make him stand out in his field. His work is not only academically significant but also socially and environmentally relevant in addressing global issues like soil degradation, crop yield loss due to climate stress, and sustainable agriculture.